X4 Pharmaceuticals Reports $1.8 Million Revenue in Q3 2025, Net Loss Improves

X4 Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the third quarter of 2025, revealing a total revenue of $1.8 million for the quarter, a substantial increase from $0.6 million in the same period last year. For the nine months ending September 30, 2025, the company generated $32.5 million in revenue, compared to just $1.1 million during the same timeframe in 2024. This growth was primarily driven by the recognition of $27.6 million in license revenue from a new agreement with Norgine Pharma UK Limited, alongside product revenue from its FDA-approved drug, XOLREMDI.

The company experienced a net loss of $29.8 million for the third quarter, an improvement from a loss of $36.7 million in the prior year. For the nine-month period, the net loss totaled $55.3 million, compared to a net income of $2.4 million in the same period of 2024, which was bolstered by a one-time gain from the sale of a non-financial asset. The increase in operating expenses, which totaled $29.3 million for the quarter, was attributed to ongoing research and development costs, as well as restructuring expenses related to workforce reductions.

In terms of strategic developments, X4 Pharmaceuticals has undergone significant organizational changes, including a workforce reduction of approximately 50% announced in September 2025, following an earlier reduction of 30% in February. These changes are part of a broader strategy to focus on the development of mavorixafor for chronic neutropenia, which is currently undergoing a pivotal Phase 3 clinical trial. The company has also closed a private placement and an underwritten public offering, raising approximately $226.6 million in total, which is expected to support its operational and financial obligations.

Operationally, X4 Pharmaceuticals reported a cash position of $69.6 million as of September 30, 2025, an increase from $55.7 million at the end of 2024. The company has also streamlined its inventory, which rose to $4.1 million from $2.8 million, reflecting its ongoing efforts to manage costs effectively. The company’s total liabilities decreased to $101.9 million from $124.3 million, primarily due to reductions in accrued expenses and accounts payable.

Looking ahead, X4 Pharmaceuticals remains focused on advancing its clinical trials and achieving regulatory milestones for mavorixafor. The company believes its current cash reserves will be sufficient to fund operations for at least the next 12 months, although it acknowledges the need for additional capital to support its long-term growth strategy. The management's outlook emphasizes the importance of successful trial outcomes and market acceptance of its products to achieve profitability in the future.